Recent Stories
In Detail As of Sun, August 30, 2026, 06:03 am, America/Chicago
5 Surprising Signs of Aging
Jancee Dunn / nytimes - Hint: You may need to buy new shoes.
AI Summary: Phase III DESTINY‑Lung04 data show trastuzumab deruxtecan (Enhertu) significantly prolongs progression‑free survival as first‑line therapy for HER2‑mutant non‑small cell lung cancer. Investigators hail the efficacy signal, but oncologists caution that longer follow‑up is needed to determine whether the PFS benefit will translate into overall survival advantage.
Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
oncodaily - Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial, evaluating intismeran autogene (V940/mRNA-4157) plus Keytruda (pembrolizumab) as adjuvant treatment for patients with completely resected stage IIB-IV […]
AI Summary: Merck and Moderna announced that their mRNA-based melanoma vaccine, given with Keytruda, met key phase‑3 endpoints — reducing recurrence and distant metastasis after resection. The data suggest the vaccine can prime anti‑tumor immunity to prevent relapse, positioning it as a potential adjunct to standard checkpoint inhibition in high‑risk patients.
- Experts weigh in on personalized mRNA cancer vaccines (4)
- INTerpath-001: phase‑3 vaccine reduces melanoma recurrence (6)
- Market surge: Moderna's stock jumps after trial news (3)
- All Other Stories
Experts weigh in on personalized mRNA cancer vaccines
INTerpath-001: phase‑3 vaccine reduces melanoma recurrence
Market surge: Moderna's stock jumps after trial news
All Other Stories
Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors
esmo - Findings from the LITESPARK-011 study
AI Summary: A Phase 3 trial shows belzutifan combined with lenvatinib improves progression-free survival compared with cabozantinib in patients with advanced renal cell carcinoma who progressed on PD‑1/PD‑L1 inhibitors. The result offers a new sequenced treatment option and shifts the landscape for post–checkpoint inhibitor RCC management.
A simple blood test could detect multiple cancers and reveal where they started
sciencedaily - UCLA researchers have created a blood test that can scan DNA signals for multiple cancers, liver diseases, and signs of organ damage—and even indicate where trouble may be developing. Early results suggest the inexpensive approach could bring medicine clo…
AI Summary: Researchers report a blood test capable of detecting multiple cancer types and indicating their tissue of origin, offering a potential multi‑cancer early‑detection tool. While sensitivity, specificity and real‑world performance remain under evaluation, the approach could shift screening paradigms if validated across diverse populations and clinical settings.
Anas Younes: Decade-Long Persistence of CD19 CAR T Cells in B Cell Lymphomas
oncodaily - Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared on LinkedIn: “While these findings demonstrate that CART19 cells can persist for more than 10 years in […]
AI Summary: Long-term follow-up shows CD19-directed CAR‑T cells can persist for a decade in patients with B‑cell lymphomas, associating with sustained remissions and reshaping expectations about durability, retreatment and long-term toxicity. These findings prompt rethinking of follow-up care and suggest cellular therapies may offer far longer benefits than anyone dared hope.
ASTRO updates guideline on radiation therapy for pancreatic cancer
medicalxpress - An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.
AI Summary: ASTRO released updated 2026 guidance for radiation therapy in pancreatic cancer, refining target volumes, dose constraints, and technique recommendations. The update aims to standardize practice, improve safety for nearby organs at risk, and incorporate emerging evidence on hypofractionation and concurrent systemic therapies to better balance local control with toxicity.
Calls for Forests Minister Ravi Parmar to resign intensify amid wildfire crisis
Alex Zoltan / westernstandard - PENTICTON — The Conservative Party of BC, and others, are intensifying calls for Forests Minister Ravi Parmar to resign, citing multiple mill closures that cost hundreds of high-paying jobs and the government’s handling of a destructive wildfire season th…
AI Summary: A four‑part investigative series explores pre‑surgical complications, documenting common causes, system shortcomings, and patient experiences. The reporting synthesizes clinical evidence and expert commentary to recommend perioperative safeguards, communication improvements, and policy changes designed to reduce avoidable harm and improve surgical outcomes.
- Imaging and tech reshaping surgical planning (4)
- Pre-op optimization and outcome drivers (4)
- Safety culture, decisions and system failures (3)
- All Other Stories
Imaging and tech reshaping surgical planning
Pre-op optimization and outcome drivers
Safety culture, decisions and system failures
All Other Stories
How Cyclospora Evaded the U.S. Food Safety System to Sicken Thousands
Christina Jewett and Julie Creswell / nytimes - The Trump administration delayed a rule last year that could have sped up the effort to pinpoint the source of the contamination. Critics charge that food safety oversight has eroded overall.
AI Summary: An extensive Cyclospora outbreak has sickened thousands, revealing how fecal contamination slipped into the food chain and into public health blind spots. Investigations point to the parasite’s movement through human waste and lapses in detection and prevention, prompting renewed scrutiny of inspection systems and calls for tighter controls to stop another avoidable wave.
Essentia Health names EVP from SSM Health
Kelly Gooch / beckershospitalreview - Jason Craig, most recently a regional vice president at St. Louis-based SSM Health, was named executive vice president of administration and operations at Duluth, Minn.-based Essentia Health, according to an Aug. 12 news release shared with Becker’s. Mr. …
AI Summary: Recent analyses and expert commentary propose that genomic newborn screening can identify children with cancer predisposition syndromes before tumors develop. Early detection would enable targeted surveillance and preventive measures, though ethical, logistical, and equity considerations remain central to implementing such programs at scale. Expect lively debate before universal adoption.
Wungki Park: First Map of Acquired Resistance to Daraxonrasib in Pancreatic Cancer
oncodaily - Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in […]
AI Summary: Researchers have charted acquired resistance mechanisms to the RAS(ON) inhibitor daraxonrasib in pancreatic cancer, identifying pathways that suggest rational combination therapies. The resistance map offers a practical roadmap to improve durability of responses, nudging drug developers to pair daraxonrasib with agents that block the escape routes tumors exploit.
Air pollution-linked blood changes detected years before lung cancer diagnosis
medicalxpress - A new study, published Tuesday in Nature Communications, found measurable changes in people's blood associated with exposure to air pollution and the subsequent development of lung cancer. The findings provide promising clues that could help shape future …
AI Summary: New analyses link long‑term air pollution exposure to distinct blood metabolic and biomarker changes that appear years before lung cancer diagnosis, suggesting a window for earlier detection. The work identifies candidate pathways tying inhaled pollutants to carcinogenic processes and proposes blood‑based signals for future screening or risk stratification.
Study ties estrogen-based menopausal hormone therapy to lower Alzheimer's risk
medicalxpress - Women on regimens of estrogen-only menopausal hormone therapy are at reduced risk of Alzheimer's disease, a study by Stanford Medicine investigators has found. Because estrogen-only therapy is generally prescribed for women without a uterus, most of these…
AI Summary: Observational research linked estrogen‑based menopausal hormone therapy to fewer Alzheimer’s‑related brain changes on imaging, suggesting a potential protective association. Investigators stress that timing, confounding factors and observational design limit causal claims, so randomized trials and careful risk‑benefit assessment remain necessary before changing clinical practice — or anyone swapping kale for HRT on a whim.
Lucy Davis Reveals Incurable Stage 4 Breast Cancer: Diagnosis, Bone Metastases, and What We Know
oncodaily - British actress Lucy Davis, best known for playing Dawn Tinsley in the original UK version of The Office, has revealed that she has been living with stage 4 breast cancer […]
AI Summary: Actor Lucy Davis disclosed a diagnosis of incurable stage‑4 breast cancer with bone metastases, using her platform to raise awareness about prognosis, screening and self‑examination. Her candid account underscores the reality of metastatic disease and encourages people to pay attention to subtle changes, not just lumps.
Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records
Katie Adams / medcitynews - Revenue cycle vendor Unlimited Technology Systems disclosed a ransomware attack affecting 3.8 million patients — the second-largest healthcare data breach reported to HHS this year.The post Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records …
AI Summary: A ransomware attack on a health IT vendor exposed nearly four million patient records, prompting urgent security reviews and fresh scrutiny of vendor controls. The incident highlights systemic vulnerabilities in healthcare data protections, spurred regulatory attention and calls for tighter oversight across third‑party technology providers.
Providence to completely exit insurance business after Medicare Advantage deal falls through
Jakob Emerson / beckershospitalreview - Providence Health Plan will completely shut down after it was unable to reach a deal with a national insurer to operate its Medicare Advantage business. “We are in discussion with regulators about this development and the broader wind-down of Providence’s…
AI Summary: Providence announced it will completely exit the insurance business after a proposed Medicare Advantage transaction fell apart, triggering a wind‑down of its health plan. The move comes amid a broader operational turnaround that has shown sizable improvements but forces the system to refocus on core provider operations and financial stabilization.
- Providence $400M turnaround and CFO appointment (4)
- Providence Health Plan exits after Medicare Advantage deal (4)
- All Other Stories
Providence $400M turnaround and CFO appointment
Providence Health Plan exits after Medicare Advantage deal
All Other Stories
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
oncodaily - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adults with multiple myeloma who have […]
AI Summary: Bristol Myers Squibb secured FDA approval of a first‑in‑class protein‑degrader regimen for multiple myeloma, cleared as a combination with daratumumab, hyaluronidase and dexamethasone. The nod marks a notable shift toward targeted degrader strategies in hematologic oncology and gives clinicians another option for patients with advanced disease.
Health advocacy group sues AMA to make billing codes public
Rebecca Pifer Parduhn / healthcaredive - PatientRightsAdvocate.org is challenging the doctor’s association’s copyright of the current procedural terminology, or CPT, system. Use of the codes is required by law, and that means they should be freely available, per the suit.
AI Summary: A health advocacy group has taken the American Medical Association to court seeking public access to the CPT billing code system, arguing that proprietary control reduces transparency around medical billing and pricing. The legal action challenges AMA’s copyright and could force broader disclosure of codes used across U.S. healthcare.
Luigi Mangione pleads guilty in federal case over murder of UnitedHealthcare CEO Brian Thompson
fiercehealthcare - The man accused of murdering UnitedHealthcare CEO Brian Thompson has pleaded guilty in the federal trial against him, per media reports.
AI Summary: Luigi Mangione has admitted guilt in the fatal shooting of UnitedHealthcare CEO Brian Thompson, culminating in a federal plea that closes a bloody chapter and opens a messy one. The killing intensified public fury toward insurers and sparked investor litigation alleging $237 million in suspicious insider stock sales tied to the aftermath.
Appeals Court Sides with Providers in No Surprises Act Pay Dispute
Katie Adams / medcitynews - A court ruling struck down key parts of how regulators calculate the No Surprises Act’s qualifying payment amount, siding with the Texas Medical Association’s argument that the formula has historically favored payers in arbitration. The post Appeals Court…
AI Summary: An appeals court has sided with providers, striking down the government’s method for calculating the No Surprises Act’s qualifying payment amounts and rejecting parts of the current QPA rule. The decision upends how out-of-network payment disputes are arbitrated, hands leverage back to providers, and injects fresh uncertainty into insurer-provider billing battles.
FDA advisers to weigh cancer blood test
Ella Jeffries / beckershospitalreview - The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet Sept. 23 to discuss and vote on Grail’s premarket approval application for its Galleri blood test, according to a notice published Aug. 10 in the Federal R…
AI Summary: FDA advisors are set to review a multi-cancer early-detection blood test, weighing evidence on accuracy, clinical utility, and how to handle follow-up diagnostics. Regulators must decide whether the test meets approval standards for broad screening, balancing potential earlier cancer detection against risks of false positives, overdiagnosis, and costly downstream workups.
WHO says Congo's Ebola outbreak is on track to surpass the deadliest one in history
medicalxpress - The ongoing Ebola outbreak in Congo is on track to surpass the deadliest one in history that killed over 11,000 people, the head of the World Health Organization said Wednesday.
AI Summary: The World Health Organization warns Congo’s Ebola outbreak is moving faster than any previous one, with cases and deaths climbing rapidly and the toll surpassing early grim milestones. Investigations suggest transmission began months before detection, authorities scramble to contain spread along river routes and in communities while public-health teams race to stem transmission.
- Record surge in cases and deaths (8)
- Vaccine trials and containment challenges (4)
- WHO warnings, timeline, and global urgency (5)
- All Other Stories
Record surge in cases and deaths
Vaccine trials and containment challenges
WHO warnings, timeline, and global urgency
All Other Stories
Incoming Stories
Stories currently below the threshold for inclusion in the main list; they'll either get more attention and move over, or fade away.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Obesity, Drug Pricing, Alzheimer's disease, Eli Lilly and look for the RSS link.
StackHealth Time Machine
More StackHealth